# Investigating the Utility of Explainable Artificial Intelligence for Neuroimaging‐Based Dementia Diagnosis and Prognosis

**Authors:** Sophie A. Martin, An Zhao, Jiongqi Qu, Phoebe Imms, Andrei Irimia, Frederik Barkhof, James H. Cole

PMC · DOI: 10.1002/hbm.70456 · Human Brain Mapping · 2026-02-02

## TL;DR

This paper explores how explainable AI can help diagnose and predict dementia using brain scans, making AI decisions more transparent and trustworthy.

## Contribution

The study proposes a framework for interpreting XAI methods in dementia diagnosis and prognosis using MRI data.

## Key findings

- Models achieved 81% accuracy for Alzheimer's diagnosis and 67% for MCI prognosis prediction.
- Gradient-based XAI methods showed strong convergence on brain regions relevant to Alzheimer's.
- Mean saliency improved MCI prognosis prediction when used as an additional input feature.

## Abstract

Artificial intelligence and neuroimaging enable accurate dementia prediction but often involve ‘black box’ models that can be difficult to trust. Explainable artificial intelligence (XAI) aims to provide insights into the model's decisions; however, choosing the most appropriate method is non‐trivial and often context‐specific. We used T1‐weighted MRI to train models on two tasks: Alzheimer's disease (AD) classification (diagnosis) and predicting conversion from mild‐cognitive impairment (MCI) to all‐cause dementia (prognosis). We applied eleven XAI methods across two popular image classification architectures, producing visualisations of the most salient regions. We also propose a framework for interpreting explanations produced by different XAI methods and predictive models. Models achieved balanced accuracies of 81% and 67% for diagnosis and prognosis. XAI outputs highlighted brain regions relevant to AD with strong convergence across gradient‐based techniques. LIME produced explanations that were most similar across architectures. Mean saliency enhanced MCI prognosis prediction when included as an additional input feature. XAI can be used to verify that models are utilising relevant features and to generate valuable measures for further analysis.

Artificial intelligence has the potential to enhance clinical decision making, but complex black box models can be difficult to interpret and trust. Explainable artificial intelligence methods aim to open the black box by highlighting which features are driving the model's prediction.

## Linked entities

- **Diseases:** Alzheimer's disease (MONDO:0004975), dementia (MONDO:0001627)

## Full-text entities

- **Genes:** SHROOM4 (shroom family member 4) [NCBI Gene 57477] {aka MRXSSDS, SHAP, shrm4}, VIT (vitrin) [NCBI Gene 5212] {aka VIT1}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}
- **Diseases:** AD (MESH:D000544), cognitive impairment (MESH:D003072), Multiple Sclerosis (MESH:D009103), MCI (MESH:D060825), pAD (MESH:C567780), Dementia (MESH:D003704), XAI (MESH:C538243), atrophy (MESH:D001284)
- **Chemicals:** NACC (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12862880/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12862880/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12862880/full.md

---
Source: https://tomesphere.com/paper/PMC12862880